In this review we discuss the application of theoretical frameworks to the interpretation of viral gene sequence data, with particular reference to the hepatitis C virus (HCV). The increasing availability of such data means that it is now possible (and necessary) to proceed from simple qualitative models of viral evolution, to more quantitative frameworks based on statistical inference, notably population genetics and molecular phylogenetics. We argue that these approaches are invaluable tools to the virologist and are essential for understanding the dynamics of viral infection and the outcome of therapeutic strategies. We use several recent HCV data-sets to illustrate the methods. ß 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Microbiological Societies.
Introduction
Traditionally, the taxonomy of viruses has not been straightforward. Very similar viruses can present radically di¡erent aetiologies and, vice versa, similar clinical outcomes may be caused by viruses di¡ering hugely in their molecular structures, cellular dynamics and replicationt he human hepatitis viruses are a prime example. We have come a long way from the ¢rst reports, more than 100 years ago, of unusual '¢lterable' infectious agents, to the establishment of modern viral gene sequence databases. Signi¢cant progress has been made during the past 20 years through the application of sequencing technology and population genetic theory, and this path is likely to continue to provide the most fruitful route towards understanding the evolution of viruses. Viral taxonomy that is not based on evolutionary (i.e. DNA or RNA sequence) criteria may have to be revised and could hinder our understanding of infectious disease.
In this review we shall go beyond the level of phylogeny and discuss how population genetic and epidemiological processes a¡ect the genetic diversity of the hepatitis C virus (HCV). HCV is currently the most widely studied and best understood positive-sense RNA virus, largely because of its enormous clinical importance. An estimated 170 million people worldwide are at risk of liver disease due to chronic HCV infection [1] and the virus is responsible for approximately 10 000 deaths per year in the United States [2] . The wealth of data being generated for HCV makes it a potential model system for studying genetic diversity in other positive-sense RNA viruses, despite the absence of a satisfactory animal model. Furthermore, HCV rarely recombines ([3] is the only example to date), which simpli¢es the application and interpretation of evolutionary analyses.
We show that an assessment of viral genetic diversity can have important implications for the clinical treatment of HCV, and that certain aspects of the aetiology of HCV infection can only be understood when genetic diversity and selective pressures are taken into account. Our discussion proceeds as follows. First we give a brief review of the theoretical frameworks that can be used to interpret viral genetic diversity. Second, we discuss the genetic diversity of HCV in the context of these frameworks, and outline its epidemiological and clinical relevance. Lastly, we describe how a simple population genetic model can be used to examine the relationship between HCV diversity and disease progression.
HCV is a single-stranded positive-sense RNA virus that belongs to the taxonomic family Flaviviridae and has a genome approximately 10 kb in length. All its proteins are encoded in a single open reading frame (see Fig. 1 ), with genes coding for structural proteins situated towards the N-terminus of the genome and non-structural genes located near the C-terminus. The structural genes code for the capsid protein (C, or Core) and the envelope glycoproteins (E1, E2). The ¢rst 27 amino acids of the E2 gene constitute the hyper variable region 1 (HVR1), which is the most variable region of the genome and appears to be involved in immune escape and disease progression. The non-structural genes code for a protease (NS2, NS3) and its cofactor (NS4A), a helicase (NS3), a protein of unknown function (NS4B), a phosphoprotein (NS5A), and an RNA-dependent RNA polymerase (NS5B). In addition, the HCV genome has 5P and 3P untranslated regions (UTRs) that are involved in the control of viral translation.
Upon cell entry, viral RNA is released and replicated in the cytoplasm. The polycistronic mRNA of the virus is translated into a single polyprotein precursor that is subsequently cleaved by a combination of viral and host proteases. The glycoproteins E1 and E2 are found in the endoplasmic reticulum, where new viral RNA appears to be enveloped. The resulting virions then bud from the endoplasmic reticulum and are released from the cell by exocytosis.
HCV replication via RNA-dependent RNA-polymerase is very error-prone and generates mutations at an estimated rate of 10 35 mutations per nucleotide per replication. This high mutation rate is the ultimate source of the virus' genetic diversity. The correct interpretation of genetic diversity should provide valuable information about the processes determining HCV transmission and disease progression.
Frameworks for understanding viral genetic diversity
Three mainstream frameworks exist for the analysis and interpretation of viral genetic diversity, (i) the quasi-species model, (ii) standard population genetics, and (iii) molecular phylogenetics. Before discussing recent experimental ¢ndings relating to HCV diversity, we ¢rst describe and compare these approaches.
The quasi-species model
Although originally conceived by Eigen [4] to model early pre-biotic evolutionary processes, the quasi-species model is frequently referred to in the viral literature, where it is usually used to denote populations containing signi¢-cant genetic variation. However, the original mathematical formulation of the quasi-species goes much further than this. In this model, the quasi-species represents a very large set of replicating nucleotide sequences. Each sequence has an associated ¢tness, a constant value that corresponds to the reproductive potential of that variant. Replication is assumed to be error-prone and thus creates sequence diversity. The sequence with the highest ¢tness is called the master sequence, but it can only persist if its ¢tness (denoted a 0 ) exceeds a 1 /Q, where a 1 is the ¢tness of the next most ¢t sequence, and Q is the error rate during replication. In other words, if a 0 s a 1 /Q is true then the master sequence will persist, if not, then the master sequence will go extinct and be replaced by its 'mutant tail' (the set of sequences that it produces during replication by mutation).
The dynamics of the quasi-species model have been exhaustively examined [5, 6] . One of the central theoretical results is that the master sequence does not dominate the population if its 'mutant tail' has a low average ¢tness. If an alternative sequence exists with a mutant tail that has a higher average ¢tness, then this alternative sequence (and its mutant tail) will come to dominate the quasi-species population. Experimental evidence of such behaviour has been reported for the vesicular stomatitis virus [7] , although this ¢nding can also be explained using nonquasi-species concepts [8] . In short, the quasi-species evolves in a deterministic fashion towards a state where a balance between selection and mutation is achieved, although stochastic models which lead to similar results have been developed.
Because the quasi-species was originally conceived to describe the biochemical evolution of RNA sequences [4] it seemed natural to apply it to RNA viruses, and it has since served as a useful conceptual model. However, the quasi-species has a number of shortcomings that limit its applicability to natural viral populations: (i) it ignores e¡ects of population size and neglects random genetic drift; (ii) it makes very strong assumptions about natural selection; in particular, it assumes that selection acts on the viral population as a whole. In contrast, conventional The genes for structural proteins (C, E1, E2, P7) are situated towards the N-terminus of the ORF. Genes coding for proteins necessary for viral replication are found towards the C-terminus of the ORF. population genetics assumes that selection acts separately on each individual genome. (iii) The quasi-species is assumed to be in mutation-selection equilibrium, whereas selection pressures in natural populations will £uctuate as a result of immune responses. (iv) Most importantly, it is very di⁄cult to adapt the quasi-species theory to make quantitative inferences from sampled viral gene sequence data.
Thus the applicability of the quasi-species framework to natural populations must be carefully assessed [8] , and the quasi-species concept should not be applied to biological systems whose essential dynamics are not solely controlled by mutation and preferential replication of some variants [6] .
Population genetics
The central quantities in population genetics are allele frequencies. The frequency of an allele is in£uenced by a combination of processes, namely mutation, recombination, natural selection and demography. In general, population genetics treats these processes as stochastic in nature, and unlike the quasi-species model, statistical methods for inferring population genetic processes from genetic data are well developed [9, 10] . In recent years, faster computers have greatly increased the power of inference methods based on coalescent theory [9] . Coalescent theory enables researchers to infer the parameters of genetic models from a small sample of gene sequences. Population genetic theory and inference are well developed disciplines, further details of which can be found in the literature [10, 11] .
The null hypothesis for population genetic inference is selective neutrality. The neutral theory of molecular evolution, originally developed by Kimura [12] and extended by Ohta [13] , assumes that most mutations are either selectively neutral or slightly deleterious. Because genetic processes are stochastic and population sizes are ¢nite, the spread of such mutations is a¡ected by random factors. Under the neutral model, if generations are discrete and non-overlapping then allele frequencies vary from generation to generation according to a binomial sampling process. This process is called random genetic drift and will lead to ¢xation of a new neutral mutation in 2N generations on average (N is the population size). If the population size is su⁄ciently small then genetic drift can even bring disadvantageous mutations to ¢xation. Of course, selectively advantageous mutations usually become ¢xed, and this occurs much more quickly than the ¢xation of a neutral variant. However, even advantageous mutations are a¡ected by genetic drift when they are rare and are occasionally lost from the population [6, 7, 9, 10] .
Considerable e¡ort has gone into debating whether the neutral model is generally applicable, and we will not add to that e¡ort here. The most important point for our current discussion is that the assumption of selective neutrality for most mutations serves as a useful, even necessary, null hypothesis for evolutionary hypothesis testing.
Molecular phylogenetics
Molecular phylogenetics is the most commonly used of the three frameworks described here and is used to reconstruct the shared history of sampled viral strains. The phylogenetic framework has two components, (i) a tree topology, representing the evolutionary relationships among the sequences, and (ii) a nucleotide substitution model, describing the processes by which the sequences have evolved. Both components can be estimated from sequence data using maximum likelihood inference methods (see [14] for a comprehensive review).
The branch lengths of a viral phylogeny typically represent genetic distances, i.e. estimates of the amount of evolutionary change among the sampled sequences. When used in this way phylogenies are simply intuitive graphical representations of the sequence data and are unconnected to population genetic models. However, population genetic concepts can be brought into the phylogenetic framework by analysing genetic distances in one of two ways.
First, normal genetic distances can be decomposed into synonymous distances (dS) and non-synonymous distances (dN) [15] . The former represents 'silent' nucleotide changes that do not alter the amino acid encoded, whereas the latter represents 'replacement' nucleotide changes that do result in a di¡erent amino acid. If the neutral theory is correct and all mutations are unselected, then synonymous and non-synonymous mutations will spread at the same rate and the ratio dN/dS will equal one. Positively selected mutations spread faster^and negatively selected mutations spread slower^than neutral mutations, so a dN/ dS ratio greater than one is interpreted as evidence for the past action of positive selection, whereas a dN/dS ratio smaller than one is thought to result from negative selection. Several statistical methods based on these principles have been developed (e.g. [16] ), but they are not applicable to every problem and can be di⁄cult to interpret [17] .
Second, genetic distances can be transformed into measures of time if the evolutionary rate of the sequences is known [6] . Adding a time scale to a phylogeny has many practical advantages, but also adds the implicit assumption that all mutations are ¢xed at the same rate (a molecular clock). This assumption is met under the neutral theory [6] .
Population genetics and molecular phylogenetics are closely related [10, 11] but di¡er in their emphasis on the evolutionary tree that relates sampled individuals. The central aim of molecular phylogenetics is the reconstruction of the tree itself, whereas in population genetic models the tree is implicitly represented but is not the focus of attention, and is thus considered as a 'nuisance variable' [9] .
The genetic diversity of HCV
With over 100 complete HCV genomes currently available, our knowledge of the genetic diversity of HCV is considerable^perhaps unsurpassed by any other organism except HIV. Like many RNA viruses, HCV shows considerable genetic diversity at the nucleotide level, generated by the high mutation rate of the virus. We now discuss how this genetic diversity, when interpreted in the context of the theoretical frameworks described above, can provide insights into the processes that determine the epidemiological (among-host) and infection (within-host) dynamics of HCV.
Genetic diversity among infected individuals
In order to impose some structure on the global genetic diversity of HCV, a classi¢cation scheme based on molecular phylogenetic analysis of viral sequences has been developed [18] . The phylogeny shown in Fig. 2 illustrates the estimated relationships among all current HCV complete genome sequences. The tree has six main branches, labelled 1^6, corresponding to the six types (or 'genotypes') of HCV [18] . Each type is phylogenetically subdivided into a number of subtypes, labelled alphabetically in their order of discovery (thus subtype 2a was identi¢ed before subtype 2c and both belong to genotype 2). More than 50 subtypes have been reported to date and are normally identi¢ed on the basis of partial gene sequences from E1 and NS5B. Only a small proportion of identi¢ed subtypes have had their entire genomes sequenced, so Fig. 2 underestimates the genetic diversity of HCV within each genotype.
Complete genomes from di¡erent types di¡er at approximately 30^35% of nucleotide sites, whereas those from di¡erent subtypes (of the same genotype) typically di¡er at about 20^25% of nucleotides (although the subtypes of type 6 are more diverse than this) [19] . The scale bar in Fig. 2 shows that the average genetic distance among HCV types is approximately one substitution per nucleotide site. As only 30^35% of nucleotides actually di¡er, there is obviously considerable heterogeneity in evolutionary rates among nucleotide sites in the genome. This heterogeneity is the result of variable evolutionary constraints. The 5P UTR contains extensive secondary RNA structure and is correspondingly the slowest evolving genomic region [20] . The next slowest region is the C (Core) gene, which evolves three times faster than the 5P UTR. The envelope genes E1 and E2 constitute the most diverse genome region and evolve about nine times faster than the 5P UTR [20] , probably as a result of their presumed role in evading the host immune response. Evolutionary constraints are also evident at the codon level: third codon positions (where approximately 70% of possible mutations are synonymous) evolve nine times faster than second codon positions (where all mutations are non-synonymous).
The six HCV types are roughly genetically equidistant from each other and there is little statistical support for phylogenetic relationships among types, thus the root of the HCV phylogeny resembles a 'star' with six arms [19, 20] . There is no obvious explanation for this pattern and none is likely to arise unless a non-human source population of HCV is found. Such populations have been found for many other members of HCV's taxonomic group, the Flaviviridae. Identi¢cation of the source of HCV should enable us to determine whether the six types originated from none, one, or several cross-species transmissions.
HCV types and subtypes exhibit complex patterns of geographic distribution, relative prevalence and modes of transmission that can be best understood by categorising them into three groups. The 'epidemic' group contains subtypes 1a, 1b, 2a, 2b and 3a, which are distributed globally and account for the majority of HCV infections worldwide [21, 22] . The rapid spread and global dissemination of these subtypes arises from their e⁄cient transmission via certain transmission routes, namely, infected blood products and injecting drug use. Subtypes 1b and 2a are more strongly associated with the former route and the relative prevalence of these subtypes has decreased in recent years due to improved blood screening [21, 24] . Subtypes 1a and 3a most often infect injecting drug users and appear to be increasing in prevalence [21, 23] .
The 'endemic' group of HCV strains are less prevalent than the epidemic subtypes and tend to have restricted geographic distributions. For example, the subtypes of type 6 are found only in South East Asia. The high genetic diversity of endemic strains points to a long period of infection in these areas, where transmission is thought to be maintained by a variety of relatively ine⁄cient social and domestic routes, including sexual transmission [22] . As HCV was only identi¢ed in 1989, di¡erences in the long-term transmission dynamics of the endemic and epidemic strains should be impossible to discover. However, using methods based on coalescent theory [9] , the epidemic history of di¡erent HCV strains can be reconstructed from observed viral genetic diversity [24] .
The third group are the 'local epidemic' strains of HCV that are found at high prevalence but only in speci¢c locations and risk groups. The best example is subtype 4a which infects more than 10% of the Egyptian population but is rare outside the Middle East. Epidemiological studies suggest that this strain was widely transmitted in Egypt during the twentieth century by mass injectable drug treatment campaigns against schistosomiasis [25] .
Taken together, these patterns suggests that the varied epidemiological behaviour of HCV types and subtypes is determined by transmission route (or the social and medical practices that generate such routes) rather than by genetic di¡erences among strains [22, 24] . If this is true, then any of the 50 or more known HCV subtypes could 'emerge' and generate a future epidemic, so long as e⁄-cient routes of transmission are available to the virus. Thus HCV genetic diversity poses a signi¢cant challenge to the prospective development of protective vaccines against HCV.
Although transmission route appears to be the dominant factor determining the global epidemiology of HCV, genetic variation among subtypes does generate signi¢cant di¡erences in clinical outcome [21] . Repeated stud- ies have shown that the response to anti-viral therapy is lower in patients with subtypes 1a, 1b and 4a than in those infected with type 2 and 3 strains [26] . Viral subtyping is therefore a useful tool in the management and treatment of chronic HCV infection. The causes of variation in treatment response are not well understood. Studies of Japanese patients infected with subtype 1b indicated that the outcome of interferon therapy was correlated with genetic variability in a portion of the NS5A gene (the interferon sensitivity determining region, ISDR) [27] , although subsequent studies of European patients could not con¢rm this result [28] .
In addition, several studies have indicated that HCV genetic diversity partially determines the variation among patients in disease progression and severity of liver disease, with the conclusion that subtype 1b infections are more likely to cause liver disease than other subtypes [21, 29] . However an equal number of studies have found no such association [21, 30] . Subtype 1b has also been linked with high rates of hepatocellular carcinoma than other subtypes (e.g. [31] ). The statistical analysis of such studies is di⁄cult, because subtype 1b is more often found in older patients, who might be expected to have more severe disease as a result of a longer period of infection.
Genetic diversity within infected individuals
The previous section touched upon di¡erences in HCV disease progression among di¡erent hosts. Here we review recent experimental results concerning the within-host evolution of HCV, with subtype 1b being the most commonly investigated strain. The studies discussed are a¡ected by a multitude of factors and often yield contradictory results. Both the number of patients investigated and number of virions extracted per patient are generally small. Moreover, the studies focus on many di¡erent viral genome regions, making it di⁄cult to draw general conclusions. Observed levels of viral diversity depend on the tissue sampled, disease stage, drug treatment, and the strength of humoral and cellular immune responses. Each of these factors are addressed in turn below.
HCV predominantly replicates in hepatocytes but low levels of replication have also been reported in peripheral blood mononuclear cells [32, 33] . Studies report di¡erences in the genetic diversity of samples taken from di¡erent tissues [34, 35] , in particular the blood and the liver [33,34,36^39] . Genetic diversity in the blood can be lower, equal, or higher than in the liver [39] . Higher diversity in the liver could result from some aspect of the viral replication process in hepatocytes, or from the accumulation of impaired sequences that are not able to leave the cell in functional virions [40] . Higher diversity in the blood is di⁄cult to explain, as levels of HCV replication outside the liver are low [39] ; it may be due to the accumulation of de¢cient virions which cannot infect liver cells. Findings are highly dependent on the genomic region investigated, and genetic di¡erences in the E1/E2 genes have been interpreted as regulating cell tropism [32] . Natural selection, whether due to immune pressure, di¡erences in viral replication rates, or cell-entry ability, may be highly variable between di¡erent tissue compartments. This puts into question the notion that a single quasi-species population exists inside each infected host [40] .
The correlation of viral diversity with disease outcome is more clear-cut. After an initial acute phase following HCV inoculation, serum levels of the virus are generally very low and the infection may be cleared spontaneously. However, in approximately 85% of cases infection becomes persistent and may cause a spectrum of diseases, ranging from minor liver damage to liver cirrhosis and hepatocellular carcinoma [2] . In a study by Farci et al. [41] , patients were grouped into four classes according to their disease outcome and genetic diversity was measured as the number of amino acid substitutions among sequences. Diversity was measured at three or more time-points; at the time of the ¢rst PCR-positive sample, just before the ¢rst PCR-positive sample, and just after sero-conversion. Despite having the highest viremia, patients with fulminant hepatitis showed the least amino acid diversity. Viral genetic diversity in resolving patients was slightly higher than in the fulminant cases, but considerably less than in those who progressed to chronic disease. In all cases, changes in genetic diversity were signi¢cantly higher in HVR1 than in other regions of the E1 and E2 genes. Crucially, it was found that non-synonymous substitutions in HVR1 were more common in rapid and slow progressors, compared to the fulminant and resolving cases. Although there are instances where complexity in the HVR1 does not seem to correlate with disease severity [42] , reports generally agree that diversity is higher in asymptomatic carriers compared to severe disease cases [41, 43, 44] . In the ¢nal section we outline a simple model that describes these observed relationships between genetic diversity and disease progression.
Because of the lack of a vaccine, great e¡ort has been invested in developing drug treatments against HCV [45] . The high mutability of the virus has unfortunately been a major obstacle for the success of most drug treatments to date. HCV anti-viral therapy involves either K-interferon alone, or interferon in combination with ribavirin [46] , but about 60% of treated patients fail to clear the virus [47] . Generally, drug response appears to be correlated with HCV diversity during the early stages of the treatment [47^51], although not necessarily with diversity before the onset of treatment [49, 52] . Diversity in non-responders is higher than in responders, suggesting that escape mutants arise [53] . Again we see signi¢cant variation between di¡erent regions in the viral genome ; at the onset of therapy diversity of the HVR1 in non-responders appears to be higher than in sustained responders [47] . However, low genetic diversity during the early stages of drug therapy is usually found to be predictive of therapy success. Viral populations in non-responders and patients who relapse tend to be characterised by one resistant strain, which may already be present before therapy in some cases [47] .
Genetic diversity is of course also a¡ected by host factors, most importantly the strength of the humoral and cellular immune responses. Over the course of an infection, immune pressure could increase diversity by repeatedly selecting for escape mutants, and individuals that are immuno-suppressed following liver transplantation have almost homogenous viral populations [44, 54, 55] . Thus the success or failure of drug treatment will almost certainly be in£uenced by the patient's immune background.
Many of the above studies are limited by their reliance on partial genome sequences and simplistic measures of viral diversity. Advances in sequencing technology mean that whole genomes should become available in the near future, providing us with a much more comprehensive picture of viral diversity. However, crude genetic diversity statistics throw away most of the information contained in sequence data and, at best, only inform us about viral mutation rate and population size. We should aim to collect viral isolates from multiple points in time, sequence large genomic regions, and analyse this data using powerful phylogenetic and population genetic methods. As an illustration, consider Fig. 3 , which shows a phylogeny of sequences taken from a patient with rapidly progressing chronic HCV infection (data from [24] ). Between the third and forth time points a new viral strain becomes ¢xed in the population, showing that a 'selective sweep' [10] has rapidly driven an advantageous variant to ¢xation. Highquality data, combined with a suitable quantitative framework for interpretation, will allow us to understand viral dynamics in much more detail than was possible previously.
A uni¢ed model of viral diversity in HCV
We have discussed three conceptual approaches that can be used to understand the genetic diversity of HCV. Recently, a simple qualitative model of genetic diversity in HIV has gained some prominence, and this model can also be straightforwardly applied to HCV [56, 57] . The model contends that viral adaptation during an infection is controlled by two principal factors: selective pressure exerted by the immune system, and viral e¡ective population size, which determines both the e⁄cacy of selection and the rate at which advantageous viral variants are produced.
The interaction of these two factors is illustrated schematically in Fig. 4 . The number of virus copies in a host will decrease as the immune response increases (green curve) thus reducing the ability of the virus to adapt. Conversely, stronger immune pressure leads to greater selection for escape mutants, which generate viral diversity (blue curve). Together these two factors give rise to a scenario that can be summarised as follows : for low levels of immune response there is little selective pressure, so very few adaptive mutations will be observed, despite a large viral population size. For high levels of immune response the viral e¡ective population size will become small and therefore selection for escape mutants will be weak. Only at intermediate levels of population size and immune selection will there be a large number of escape mutants (red curve), resulting from the strong co-evolutionary 'arms race' between the virus and the immune system. It is this ability of the virus to adapt (i.e. to generate non-neutral amino acid changes) that therapeutic approaches need to decrease.
This simple model seems to capture the essential dynamics underlying the genetic diversity of HCV and it makes sense to re-evaluate the ¢ndings of Farci et al. [41] in this context. In cases with fulminant hepatitis the immune system is too weak to control the virus, resulting in a large, homogeneous viral population. For the same reason, the model predicts that low diversity should be observed in immuno-compromised patients, as is the case [44, 54, 55] . In resolving cases, the immune system is su⁄ciently strong to reduce the selection of escape mutants by decreasing the viral population size, or is capable of dealing with those mutants that do arise, leading to intermediate levels of viral diversity. For intermediate strengths of the immune response, the virus population is only partially controlled and is therefore large enough to generate multiple escape mutants in response, resulting in chronic infection and a high observed dN/dS ratio. Thus Farci et al.'s [41] results can be described by a simple model that only incorporates selection and population size. In contrast, the quasi-species model incorporates theoretical assumptions that are not easily reconciled with realistic virus dynamics. Specifically, the quasi-species assumes that viral adaptation is not a¡ected by population size or by mutations whose ¢tnesses are frequency-dependent. The above model has the same intuitive appeal as the quasi-species, but has the advantage of being ¢rmly based on population genetic processes.
Conclusion
Viral diversity is in£uenced by a variety of factors that are not always separable. Qualitative descriptions, such as the quasi-species concept and the abovementioned population genetic model, can provide useful guides to the interpretation of genetic diversity in natural virus populations. Increasingly, however, we need to be able to assess genetic diversity more quantitatively. Population genetics and phylogenetics potentially provide us with powerful statistical frameworks to interpret observed sequence data and to make testable predictions about the outcome of proposed drug and vaccine treatments. Progress over the next few years will show if we can correctly utilise these frameworks to investigate and quantify the dynamic processes involved in virus transmission and disease progression.
